CROSS Research SA
Arzo, Via F.A. Giorgioli, 14, 6864, Switzerland
NCT Number: NCT01280175
The purpose of this study is to evaluate the systemic exposure of BDP, its metabolite beclomethasone 17-monopropionate (B17MP) and formoterol after inhalation of BDP/Formoterol 100/6 µg pMDI combination (CHF1535) using the standard actuator and charcoal block technique or using a Spacer (AeroChamber Plus, Trudell) in comparison with inhalation using the standard actuator
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Arzo, Via F.A. Giorgioli, 14, 6864, Switzerland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: from pre-dose until 12 h post-dose
Time frame: from pre-dose until 12 h post-dose
Chiesi Farmaceutici S.p.A.
Industry
Pharmacokinetics and Lung Bioavailability of BDP/Formoterol HFA Fixed Combination After Single Administration in 12 Healthy Volunteers Using the Standard Actuator With or Without Charcoal Block or the Aerochamber Spacer.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04415749
Anthrax, Bacillaceae Infections
Salt Lake City, Utah, United States
View Trial DetailsNCT03352466
Anthrax, Bacillaceae Infections
Melbourne, Florida, United States
View Trial DetailsNCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial Details